Greenwich LifeSciences, Inc. (GLSI) - Dilution Analysis

10-K filing | 13.5M shares outstanding

10-Q filing | 13.6M shares outstanding

10-Q filing | 13.2M shares outstanding

10-K filing | 13.0M shares outstanding

10-Q filing | 13.1M shares outstanding

S-3 filing: The company may offer and sell common stock, preferred stock, debt securities, warrants, or any combination thereof, with an aggregate initial offering price not exceeding $275,000,000, and is offering common stock from time to time through its sales agent H.C. Wainwright & Co., LLC up to $100,000,000.

10-Q filing | 12.9M shares outstanding

8-K filing: Greenwich LifeSciences, Inc. entered into a securities purchase agreement to issue and sell 174,825 shares of its common stock to its CEO, Snehal Patel, at $14.30 per share, with gross proceeds of approximately $2.5 million, for clinical development and working capital, expected to close on June 18, 2024. ($2.5M proceeds)

10-Q filing | 12.9M shares outstanding

10-K filing | 12.8M shares outstanding

10-Q filing | 12.8M shares outstanding

10-Q filing | 12.8M shares outstanding

10-Q filing | 12.8M shares outstanding

10-K filing | 12.8M shares outstanding

10-Q filing | 12.8M shares outstanding

10-Q filing | 12.8M shares outstanding

10-Q filing | 13.0M shares outstanding

S-3/A filing: The filing is an S-3/A form indicating a shelf registration for the potential offering of common stock, preferred stock, debt securities, and/or warrants, either individually or in combination, up to an aggregate initial offering price not exceeding $300,000,000.

S-3 filing: The company is filing an S-3 to register the offering of common stock, preferred stock, debt securities, warrants, rights to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities, having an aggregate initial offering price not exceeding $300,000,000.

10-K filing | 13.0M shares outstanding

10-Q filing | 13.1M shares outstanding

10-Q filing | 13.0M shares outstanding

10-Q filing | 12.7M shares outstanding

10-K filing | 8.5M shares outstanding

8-K filing: Greenwich LifeSciences, Inc. closed an underwritten public offering of 660,000 shares of common stock at $40.00 per share on December 22, 2020, with gross proceeds of $26.4 million before deducting underwriting discounts and commissions. ($26.4M proceeds)

S-1 filing: Greenwich LifeSciences, Inc. is filing an S-1 to offer 470,085 shares of common stock at a public offering price of $46.80 per share. The underwriters have an option to purchase an additional 70,512 shares.

10-Q filing | 12.0M shares outstanding

8-K filing: The company completed its IPO and sold 1,260,870 shares of its common stock at $5.75 per share. Also, the company filed a second amended and restated certificate of incorporation and the second amended and restated bylaws in connection with the closing of the IPO.

8-K filing: Greenwich LifeSciences, Inc. entered into an underwriting agreement with Aegis Capital Corp. to sell 1,260,870 shares of common stock at $5.75 per share in a firm commitment underwritten public offering. ($7.27M proceeds)

S-1/A filing: This is an S-1/A filing for a proposed public offering of 1,450,000 shares of common stock, a resale of 1,685,394 shares of common stock, and warrants to purchase up to 8% of the shares sold in the offering.

S-1/A filing: Initial public offering of shares of common stock. We are offering 1,260,870 shares of our common stock. We have registered an aggregate of 1,685,394 shares of our common stock for resale by certain selling stockholders by means of the Selling Stockholder Prospectus.

S-1/A filing: The filing relates to the registration of resales of common stock issuable upon exercise of underwriter warrants.

S-1/A filing: Greenwich LifeSciences, Inc. is offering 1,000,000 shares of common stock in an initial public offering, with an expected price between $7.50 and $8.50 per share. Additionally, certain selling stockholders are registering 1,685,394 shares for resale.